Efficacy results within 30 days, very very exciting! From the news..............
The Study has been designed to treat 3 patients at a lower dose of the PDC and to monitor the patients for 30 days, according to the endpoint criteria above. If successful, then an additional 6 patients will be enrolled into the Study to be treated at a higher dose of the PDC and monitored for 180 days, according to the endpoint criteria.
The next 2 patients in the Study have been enrolled and are currently scheduled for treatment.
Roger Dumoulin-White, President and CEO of Theralase stated that, “This is the first time that the Company’s PDT technology has been used in human clinical testing and represents a major milestone achievement for the Company, significantly de-risking the Company by shifting it from a pre-clinical to now a clinical biotech organization in oncology. Theralase looks forward to successfully treating the next 2 patients and reporting out on the status of the first three patients in the Study in 2Q2017.”